Biogen, UCB step up to kick the tires at Acorda as buyout buzz grows — report
Acorda $ACOR CEO Ron Cohen appears to have stirred up some high-level interest in a potential auction.
Rumors have been swirling that days after the biotech reportedly brought in advisers to help prep for a sale, some bidders have begun to step up to the table. And early Friday Bloomberg reported that Biogen and UCB have stepped up to kick the tires, along with possible interest from Asian drugmakers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.